Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
NCT00003105 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2013-07-03
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic or locally advanced bladder cancer.
Conditions
- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
- BIOLOGICAL
- DRUG
- DRUG
-
doxorubicin hydrochloride
- DRUG
-
gemcitabine hydrochloride
- DRUG
-
ifosfamide
- DRUG
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Dean F. Bajorin, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-09-30
- Primary Completion
- 2004-08-31
- Completion
- 2004-08-31
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
NCT00002919 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00005791 ·Status: COMPLETED ·Phase: PHASE1
-
Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT02420847 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
NCT00003376 ·Status: COMPLETED ·Phase: PHASE3
-
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
NCT00006105 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00003742 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
NCT00478361 ·Status: COMPLETED ·Phase: PHASE2
-
Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer
NCT00003055 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
NCT00005644 ·Status: COMPLETED ·Phase: PHASE2
-
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
NCT00022191 ·Status: COMPLETED ·Phase: PHASE3
-
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
NCT00055835 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
NCT00014287 ·Status: WITHDRAWN ·Phase: PHASE1
-
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
NCT01639521 ·Status: WITHDRAWN ·Phase: PHASE2
-
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
NCT00022633 ·Status: TERMINATED ·Phase: PHASE2
-
BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
NCT00043095 ·Status: COMPLETED ·Phase: PHASE1
-
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
NCT00389155 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
NCT01524991 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
NCT03093922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
NCT00002559 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT02375204 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00006372 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
NCT00014274 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00004242 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
NCT00089128 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00004913 ·Status: COMPLETED ·Phase: PHASE1